InfuSystem expects 2026 pro forma revenue growth of 6%-8%
INFU•InfuSystem forecasts 2026 pro forma revenue growth of 6%-8% and an adjusted EBITDA margin in the low-to-mid 20% range. For 2025, revenue rose 6% to $143.4 million and adjusted EBITDA increased 25% to $31.5 million.
1. 2026 outlook
InfuSystem expects 2026 pro forma revenue growth of 6%-8%, with an adjusted EBITDA margin in the low-to-mid 20% range. Its long-term adjusted EBITDA margin target is 22%-25%, compared with 22.9% for the trailing 12 months through September 30, 2026.
2. Margin drivers
The company said completed infrastructure investments, improved billing efficiency and growth in less capital-intensive therapies are expected to support margin expansion.
3. 2025 results
Revenue in 2025 reached $143.4 million, up 6%, while adjusted EBITDA rose 25% to $31.5 million.
